Canada approves Merck grass allergy immunotherapy

by The Associated Press

Merck & Co. says it's won its first approval for its new immunotherapy tablet for grass allergies, from regulators in Canada.

The drug, called Grastek, gradually reduced to grass pollen, by desensitizing the immune system to the substance triggering the allergic reaction. Most treatments just temporarily relieve sneezing, itching and other symptoms.

The world's third-biggest drugmaker, based in Whitehouse Station, N.J., has partnered with ALK-Abello to market it in North America. ALK-Abello sells it in Europe as Grazas.

In the U.S., the Food and Drug Administration is weighing approval of both Grastek and an immunotherapy tablet for ragweed allergies. The tablets dissolve under the tongue and are taken daily for a year or so.

They could become an alternative to months of uncomfortable allergy shots.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Merck says FDA reviewing its ragweed allergy therapy

May 08, 2013

Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, ...

Merck: FDA reviewing tablet to eliminate allergy

Mar 27, 2013

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that gradually reduces allergy symptoms over time, rather than just temporarily relieving ...

Recommended for you

Flame retardants linked to preterm birth

Jan 28, 2015

Researchers at The University of Texas Medical Branch have determined that maternal exposure to high levels of flame-retardants may be a contributing factor in preterm births.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.